Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pink

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levelsKathryn E Reinicke, Erik A Bey, Melissa S Bentle, et al.
Journal of Cellular Physiology|September 27, 2006
Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responsesErik A Bey, Shelly M Wuerzberger-Davis, John J Pink, et al.
Investigational New Drugs|June 20, 2020
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumorsJennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, et al.
Molecular Cancer Therapeutics|July 26, 2013
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancersErik A Bey, Kathryn E Reinicke, Melissa C Srougi, et al.
The Journal of Clinical Investigation|October 22, 2024
Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical modelsTing-Yu Chang, Yan Yan, Zih-Yao Yu, et al.
Current Oncology (Toronto, Ont.)|June 4, 2020
A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomesS Ahmed, L Barbera, S J Bartlett, et al.
Contemporary Clinical Trials|September 14, 2025
TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder Breast Cancer Patients (THRIVE 65)Kathryn H Schmitz, Nathan A Berger, Cynthia Owusu, et al.
Vox Sanguinis|December 17, 2013
Should DEHP be eliminated in blood bags?P F van der Meer, H W Reesink, S Panzer, et al.
Vox Sanguinis|August 27, 2016
International Forum regarding practices related to donor haemoglobin and ironM Goldman, K Magnussen, J Gorlin, et al.
Vox Sanguinis|May 8, 2014
Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of careL Lieberman, D V Devine, H W Reesink, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levelsKathryn E Reinicke, Erik A Bey, Melissa S Bentle, et al.
Journal of Cellular Physiology|September 27, 2006
Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responsesErik A Bey, Shelly M Wuerzberger-Davis, John J Pink, et al.
Investigational New Drugs|June 20, 2020
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumorsJennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, et al.
Molecular Cancer Therapeutics|July 26, 2013
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancersErik A Bey, Kathryn E Reinicke, Melissa C Srougi, et al.
The Journal of Clinical Investigation|October 22, 2024
Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical modelsTing-Yu Chang, Yan Yan, Zih-Yao Yu, et al.
Current Oncology (Toronto, Ont.)|June 4, 2020
A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomesS Ahmed, L Barbera, S J Bartlett, et al.
Contemporary Clinical Trials|September 14, 2025
TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder Breast Cancer Patients (THRIVE 65)Kathryn H Schmitz, Nathan A Berger, Cynthia Owusu, et al.
Vox Sanguinis|December 17, 2013
Should DEHP be eliminated in blood bags?P F van der Meer, H W Reesink, S Panzer, et al.
Vox Sanguinis|August 27, 2016
International Forum regarding practices related to donor haemoglobin and ironM Goldman, K Magnussen, J Gorlin, et al.
Vox Sanguinis|May 8, 2014
Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of careL Lieberman, D V Devine, H W Reesink, et al.
Pageof 10